SanofiSNY stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent, a ...

Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after ...

Amlitelimab study met its goals but results were not meaningfully better than Dupixent ...

Sanofi (SNY) announced on Thursday that its experimental drug, Amlitelimab, met all primary and key secondary endpoints in a ...

Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug ...

Sanofi stated that these positive results strengthen amlitelimab's potential as a treatment for atopic dermatitis. The company is currently conducting additional late-stage trials of the drug, which ...

Amlitelimab has been billed by Sanofi as a successor to its Regeneron-partnered, $14.5 billion blockbuster Dupixent ...

Amlitelimab showed efficacy in skin clearance compared to a placebo, but the results underwhelmed investors.

French drugmaker Sanofi SA (NASDAQ:SNY) stock fell sharply Thursday after late-stage trial results for amlitelimab, its ...

An effort by President Trump’s administration to curb advertising for pharmaceutical drugs on television is posing a ...

European shares closed higher on Thursday as heightened expectations for a U.S. Federal Reserve interest rate cut lifted ...

Eczema can be very distressing for children – and now it seems that its roots may at least partly lie in their mothers ...